13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)

Page 2 of 10

Page 2 of 10 – SEC Filing


Schedule 13D

CUSIP No. 00484M106
  (1) 

Name of
Reporting Persons:

Scopia Capital Management LP

  (2)

Check the Appropriate Box if a Member
of a Group (See Instructions):

(a)  ☐        (b)  ☐

  (3)

SEC Use Only:

  (4)

Source of Funds (See
Instructions):

AF

  (5)

Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐

  (6)

Citizenship or Place of
Organization:

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH:

  (7) 

Sole Voting Power

0

  (8)

Shared Voting Power

7,708,527

  (9)

Sole Dispositive Power

0

(10)

Shared Dispositive Power

7,708,527

(11)

Aggregate Amount Beneficially Owned by Each Reporting Person:

7,708,527

(12)

Check if the Aggregate Amount in Row
(11) Excludes Certain Shares (See Instructions):  ☐

(13)

Percent of Class Represented by Amount
in Row (11):

16.5%*

(14)

Type of Reporting Person (See
Instructions):

PN, IA

* Based on 46,659,426 shares of Common Stock of Acorda Therapeutics, Inc. (the Issuer) outstanding as of April 30, 2017, as reported in the Issuers Form 10-Q filed with the Securities and Exchange
Commission (SEC) on May 9, 2017.

Follow Acorda Therapeutics Inc. (NASDAQ:ACOR)

Page 2 of 10